NO20054169L - 3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer. - Google Patents

3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer.

Info

Publication number: NO20054169L
Authority: NO; Norway
Prior art keywords: propylcarbamoyl; benzothiazol; cycloalkyl; inhibitors; acid derivatives
Prior art date: 2003-03-14

Application number

NO20054169A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054169D0 (no

Inventor

David Hepworth

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-14

Filing date

2005-09-07

Publication date

2005-12-07

2003-03-14 Priority claimed from GB0305916A external-priority patent/GB0305916D0/en

2003-12-16 Priority claimed from GB0329143A external-priority patent/GB0329143D0/en

2005-09-07 Application filed by Pfizer filed Critical Pfizer

2005-09-07 Publication of NO20054169D0 publication Critical patent/NO20054169D0/no

2005-12-07 Publication of NO20054169L publication Critical patent/NO20054169L/no

Links

239000003112 inhibitor Substances 0.000 title abstract 4
-1 1,3-benzothiazol-6-yl Chemical group 0.000 title 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title 1
125000000753 cycloalkyl group Chemical group 0.000 title 1
206010057671 Female sexual dysfunction Diseases 0.000 abstract 4
208000021663 Female sexual arousal disease Diseases 0.000 abstract 2
102000003729 Neprilysin Human genes 0.000 abstract 2
108090000028 Neprilysin Proteins 0.000 abstract 2
206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Addiction (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Pregnancy & Childbirth (AREA)

NO20054169A 2003-03-14 2005-09-07 3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer. NO20054169L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0305916A GB0305916D0 (en)	2003-03-14	2003-03-14	New N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors
GB0329143A GB0329143D0 (en)	2003-12-16	2003-12-16	Novel pharmaceuticals
PCT/IB2004/000822 WO2004080985A1 (en)	2003-03-14	2004-03-09	3-(1-[3-(1,3-benzothiazol-6-yl)propylcarbamoyl]cycloalkyl)propanoic acid derivatives as nep inhibitors

Publications (2)

Publication Number	Publication Date
NO20054169D0 NO20054169D0 (no)	2005-09-07
NO20054169L true NO20054169L (no)	2005-12-07

Family

ID=32992599

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054169A NO20054169L (no)	2003-03-14	2005-09-07	3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer.

Country Status (25)

Country	Link
US (1)	US20040180941A1 (is)
EP (1)	EP1606272A1 (is)
JP (1)	JP3923512B2 (is)
KR (1)	KR20050110003A (is)
AP (1)	AP2005003393A0 (is)
AR (1)	AR043551A1 (is)
AU (1)	AU2004220269A1 (is)
BR (1)	BRPI0408377A (is)
CA (1)	CA2519072A1 (is)
CL (1)	CL2004000512A1 (is)
EA (1)	EA200501204A1 (is)
EC (1)	ECSP056017A (is)
HR (1)	HRP20050797A2 (is)
IS (1)	IS8003A (is)
MA (1)	MA27720A1 (is)
MX (1)	MXPA05009788A (is)
NL (1)	NL1025709C2 (is)
NO (1)	NO20054169L (is)
OA (1)	OA13039A (is)
PA (1)	PA8597401A1 (is)
PE (1)	PE20050310A1 (is)
TN (1)	TNSN05227A1 (is)
TW (1)	TW200504038A (is)
UY (1)	UY28226A1 (is)
WO (1)	WO2004080985A1 (is)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2007001348A (es) *	2004-08-02	2008-03-11	Bebaas Inc	Composiciones de vitamina b12.
WO2006027680A1 (en) *	2004-09-10	2006-03-16	Pfizer Limited	3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
PT1830869E (pt)	2004-12-24	2013-08-22	Spinifex Pharm Pty Ltd	Método de tratamento ou profilaxia
AU2006275702A1 (en)	2005-07-29	2007-02-08	Concert Pharmaceuticals Inc.	Novel pharmaceutical compounds
US20070178141A1 (en) *	2005-09-07	2007-08-02	Bebaas, Inc.	Vitamin B12 compositions
US20130131007A1 (en)	2005-09-07	2013-05-23	Bebaas, Inc.	Vitamin b12 compositions
CA2646379C (en) *	2006-03-20	2014-12-23	The University Of Queensland	Method of treatment or prophylaxis inflammatory pain
WO2008021666A2 (en) *	2006-08-18	2008-02-21	Morton Grove Pharmaceuticals, Inc.	Stable liquid levetiracetam compositions and methods
KR101177866B1 (ko)	2011-03-24	2012-08-28	주식회사 케이엠더블유	케이블 접속 장치
WO2019241585A1 (en) *	2018-06-14	2019-12-19	Astrazeneca Uk Limited	Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
US20190385720A1 (en) *	2018-06-14	2019-12-19	AstraZeneca UK Litimited	Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
BR112021005532A2 (pt)	2018-09-25	2021-06-29	Antabio Sas	composto, composição farmacêutica e combinação
AU2020377914A1 (en) *	2019-11-08	2022-06-02	Vella Bioscience, Inc.	Peripherally acting cannabidiol(CBD)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders
GB202402524D0 (en) *	2024-02-22	2024-04-10	Futura Medical Developments Ltd	Topical composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2503059A (en) *		1950-04-04		Nxchj
US2599000A (en) *	1950-09-02	1952-06-03	Smith Kline French Lab	Nu, nu-disubstituted-beta-halo-alkylamines
US3238215A (en) *	1963-10-17	1966-03-01	Sterling Drug Inc	1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
IT1066857B (it) *	1965-12-15	1985-03-12	Acraf	Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3511836A (en) *	1967-12-13	1970-05-12	Pfizer & Co C	2,4,6,7-tetra substituted quinazolines
NL175059C (nl) *	1974-02-23		Boehringer Mannheim Gmbh	Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.
US4026894A (en) *	1975-10-14	1977-05-31	Abbott Laboratories	Antihypertensive agents
US4188390A (en) *	1977-11-05	1980-02-12	Pfizer Inc.	Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
FR2421888A1 (fr) *	1978-02-06	1979-11-02	Synthelabo	Amides d'alkylene-diamines et leur application en therapeutique
IT1094076B (it) *	1978-04-18	1985-07-26	Acraf	Cicloalchiltriazoli
JPS56110665A (en) *	1980-02-08	1981-09-01	Yamanouchi Pharmaceut Co Ltd	Sulfamoyl-substituted phenetylamine derivative and its preparation
DE3528032A1 (de) *	1985-08-05	1987-02-05	Hoechst Ag	Verfahren zur herstellung 2-substituierter benzthiazole
PT100905A (pt) *	1991-09-30	1994-02-28	Eisai Co Ltd	Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
CA2189355A1 (en) *	1995-03-01	1996-09-06	Yasuo Onoda	Imidazoquinazoline derivatives
GB9518953D0 (en) *	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
US6037346A (en) *	1997-10-28	2000-03-14	Vivus, Inc.	Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO2002079143A1 (en) *	2001-03-28	2002-10-10	Pfizer Limited	N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad

2004
- 2004-03-08 PA PA20048597401A patent/PA8597401A1/es unknown
- 2004-03-09 KR KR1020057017229A patent/KR20050110003A/ko not_active Ceased
- 2004-03-09 EA EA200501204A patent/EA200501204A1/ru unknown
- 2004-03-09 HR HR20050797A patent/HRP20050797A2/hr not_active Application Discontinuation
- 2004-03-09 AU AU2004220269A patent/AU2004220269A1/en not_active Abandoned
- 2004-03-09 MX MXPA05009788A patent/MXPA05009788A/es unknown
- 2004-03-09 CA CA002519072A patent/CA2519072A1/en not_active Abandoned
- 2004-03-09 EP EP04718706A patent/EP1606272A1/en not_active Withdrawn
- 2004-03-09 JP JP2006500337A patent/JP3923512B2/ja not_active Expired - Fee Related
- 2004-03-09 AP AP2005003393A patent/AP2005003393A0/xx unknown
- 2004-03-09 OA OA1200500261A patent/OA13039A/en unknown
- 2004-03-09 WO PCT/IB2004/000822 patent/WO2004080985A1/en not_active Ceased
- 2004-03-09 BR BRPI0408377-6A patent/BRPI0408377A/pt not_active IP Right Cessation
- 2004-03-10 PE PE2004000259A patent/PE20050310A1/es not_active Application Discontinuation
- 2004-03-11 AR ARP040100785A patent/AR043551A1/es unknown
- 2004-03-11 UY UY28226A patent/UY28226A1/es not_active Application Discontinuation
- 2004-03-12 NL NL1025709A patent/NL1025709C2/nl not_active IP Right Cessation
- 2004-03-12 TW TW093106666A patent/TW200504038A/zh unknown
- 2004-03-12 CL CL200400512A patent/CL2004000512A1/es unknown
- 2004-03-12 US US10/800,065 patent/US20040180941A1/en not_active Abandoned
2005
- 2005-08-29 IS IS8003A patent/IS8003A/is unknown
- 2005-09-07 NO NO20054169A patent/NO20054169L/no not_active Application Discontinuation
- 2005-09-14 TN TNP2005000227A patent/TNSN05227A1/fr unknown
- 2005-09-14 EC EC2005006017A patent/ECSP056017A/es unknown
- 2005-09-14 MA MA28498A patent/MA27720A1/fr unknown

Also Published As

Publication number	Publication date
HRP20050797A2 (en)	2006-02-28
JP2006526572A (ja)	2006-11-24
EP1606272A1 (en)	2005-12-21
PA8597401A1 (es)	2005-05-24
CL2004000512A1 (es)	2005-01-21
UY28226A1 (es)	2004-11-08
ECSP056017A (es)	2006-01-27
IS8003A (is)	2005-08-29
JP3923512B2 (ja)	2007-06-06
NL1025709A1 (nl)	2004-09-16
EA200501204A1 (ru)	2006-06-30
TW200504038A (en)	2005-02-01
OA13039A (en)	2006-11-10
AU2004220269A1 (en)	2004-09-23
PE20050310A1 (es)	2005-05-04
US20040180941A1 (en)	2004-09-16
CA2519072A1 (en)	2004-09-23
BRPI0408377A (pt)	2006-03-21
MXPA05009788A (es)	2005-10-26
MA27720A1 (fr)	2006-01-02
NL1025709C2 (nl)	2005-03-14
KR20050110003A (ko)	2005-11-22
AP2005003393A0 (en)	2005-09-30
NO20054169D0 (no)	2005-09-07
WO2004080985A1 (en)	2004-09-23
TNSN05227A1 (fr)	2007-06-11
AR043551A1 (es)	2005-08-03

Legal Events

Date	Code	Title	Description
2008-10-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20054169L (no)	2005-12-07	3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer.
NO20052796L (no)	2005-06-09	Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20053627L (no)	2005-08-10	Malonamidderivater som gamma-sekretase inhibitorer
NO20083411L (no)	2004-03-19	Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling
BR0310106A (pt)	2005-02-22	Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
NO20051189L (no)	2005-05-10	1,3-diamino-2-hydroksypropan prodrogederivater
NO20082496L (no)	2008-07-24	Pyrazinderivater
NO20063761L (no)	2006-10-23	Sulfonamidderivater for behandling av sykdommer
TW200728305A (en)	2007-08-01	Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
MXPA03011484A (es)	2004-03-18	Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
EP1689713A4 (en)	2009-02-18	BENZYL ETHER AND BENZYLAMINE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
TW200512195A (en)	2005-04-01	Benzamide 2-hydroxy-3-diaminoalkanes
BRPI0409627A (pt)	2006-04-25	2-hidróxi-3-diaminoalcanos de fenacila
ATE489951T1 (de)	2010-12-15	Thiazolidin-carbonsäureamid-derivate als modulatoren des prostaglandin-f-rezeptors
NO20056192L (no)	2005-12-27	Kapaseinhibitorer og anvendelse derav
CY1111327T1 (el)	2015-08-05	Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
NO20083708L (no)	2008-09-23	4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20076000L (no)	2008-01-28	Aminosyrederivater
NO20060314L (no)	2006-04-06	Nicotinamid-derivater anvendbare som PDE4-inhibitorer
EP1817312A4 (en)	2009-11-04	MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
NO20051146L (no)	2005-04-18	Fremgangsmate for fremstilling av mellomprodukter nyttige for fremstilling av tubulininhibitorer
EP2077719A4 (en)	2010-12-08	PIPERIDINE AND PYRROLIDIN BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
NO20051011L (no)	2005-05-02	Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister
NO20064982L (no)	2006-10-31	1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav
MXPA03001314A (es)	2004-04-05	Proceso para la preparacion de alfa'-clorocetonas.